As far as I’m aware there are only 2 dossiers that ACR currently has FDA approval for but have not been launched. Elma and Jublia. So there’s currently 6 dossiers ( jublia- testosterone- Elma- Actuylar - Dapsone x 2 different strengths) but only 3 approvals
Elma has not been launched due to Harris Pharma Bankruptcy
Jublia due conditions of court settlement that have been confidential since 2017
Did anyone catch how the pipeline is going, when they hope to submit the next dossier. We are supposed to have 10 dossiers all up with the FDA by 31st Dec 2022 ?
Ann: Chairman and CEO address to AGM, page-11
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.69M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 60019 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 225945 | 1 |
View Market Depth
| Last trade - 16.12pm 18/09/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable